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Atrial ﬁbrillation is the most common cardiac arrhythmia mainly caused by valvular, ischemic, hypertensive, and myopathic heart
disease. Atrial ﬁbrillation can occur in families suggesting a genetic background especially in younger subjects. Additionally recent
studies have identiﬁed common genetic variants to be associated with atrial ﬁbrillation in the general population. This cardiac
arrhythmia has important public health implications because of its main complications: congestive heart failure and ischemic
stroke. Since atrial ﬁbrillation can result in ischemic stroke, one might assume that genetic determinants of this cardiac arrhythmia
are also implicated in cerebrovascular disease. Ischemic stroke is a multifactorial, complex disease where multiple environmental
and genetic factors interact. Whether genetic variants associated with a risk factor for ischemic stroke also increase the risk of
a particular vascular endpoint still needs to be conﬁrmed in many cases. Here we review the current knowledge on the genetic
background of atrial ﬁbrillation and the consequences for cerebrovascular disease.
1.Introduction
Of all cardiac arrhythmias, atrial ﬁbrillation (AF) is the most
common, aﬀecting approximately 1-2% of the population
[1] .T h ep r e v a l e n c ei sh i g h e ri nm e nc o m p a r e dt ow o m e n
and increases with age, which is reﬂected by the ﬁnding
that 25% of the population aged over 40 will develop AF
[2]. Patients with AF frequently have other cardiovascular
and noncardiovascular comorbidities, the most important
condition being hypertension [3], which is an important risk
factor for the development of AF [4]. AF is not a benign
disease as it is associated with increased rates of death,
stroke, ischemic heart disease, heart failure, and peripheral
thrombo-embolic events. In patients with AF, various inde-
pendentfactorsraisetheriskofstrokesuchasthepresenceof
hypertension, advancing age and diabetes and the previous
occurrence of a stroke or transient ischemic attack (TIA)
[5, 6]. Epidemiological studies have identiﬁed various risk
factors for AF which include age, male sex, hypertension
and the presence of structural heart abnormalities. However,
it was suspected that the totality of the risk could not be
explained exclusively by these factors, and a genetic risk
component was suspected [7]. Although the vast majority
of AF is sporadic and nonfamilial, familial (hereditary)
f o r m so fA Fh a v eb e e ni d e n t i ﬁ e d( Table 1). Also, the genetic
backgroundofAFinthegeneralpopulationhasbeenstudied
through association studies (Table 1) .S i n c es t r o k ei sam a j o r
complication of AF, genetic variants associated with this
arrhythmia may be implicated in ischemic cerebrovascular
disease. We present an overview of the current knowledge in
themonogenicformsandcomplexgeneticsofAFanddiscuss
the consequences for ischemic stroke.
2.Pathophysiology
Various structural cardiac abnormalities can result in a pro-
cess of remodeling in the ventricles and atria. This remod-
eling is characterized by the proliferation of myoﬁbroblasts2 Stroke Research and Treatment
Table 1: Genetics of atrial ﬁbrillation.
Gene/Locus Mechanism of action Study design/Inheritance
Sodium channels SCNA5 [8–17]
Cellular hyperexcitability (gain-of-function)
as well as prolongation of the atrial action
potential duration (loss-of-function)
Candidate gene/Familial and sporadic
SCN1B/SCN2B [18] Decreased peak sodium current amplitude Candidate gene/Sporadic
Potassium channels
KCNQ1 [19–22] Enhanced atrial action potential
repolarization
Linkage/Familial
KCNE2 [23] Enhanced atrial action potential
repolarization
Candidate gene/Familial
KCNJ2 [24] Enhanced atrial action potential
repolarization
Candidate gene/Familial
KCNE5 [25] Enhanced atrial action potential
repolarization
Candidate gene/Familial and sporadic
KCNA5 [26–28] Delayed atrial action potential
repolarization
Candidate gene/Familial and sporadic
Other
NPPA [29] Shortening of the atrial action potential
duration
Linkage/Familial
GJA5 [30–32] Dispersion of conduction velocity Candidate gene/Sporadic
10q22 [33] Unknown Linkage/Familial
6q14–16 [34] Unknown Linkage/Familial
5p15 [35] Unknown Linkage/Familial
4q25 (PITX2) [36, 37] Unknown Genome wide association/Sporadic
16q22 (ZFHX3) [38] Unknown Genome wide association/Sporadic
1q21 (KCNN3) [39] Unknown Genome wide association/Sporadic
and the development of ﬁbrosis. Interstitial ﬁbrosis leads to
electrical uncoupling and conduction slowing, which pro-
motes AF. If atrial ﬁbrillation persists for several days, elec-
trical and structural remodeling occurs promoting further
maintenance of AF [40, 41]. Electrophysiologically several
mechanismshavebeenidentiﬁedwhichtriggerandmaintain
the arrhythmia.
The mechanisms by which AF becomes thrombogenic
are complex and have not been completely elucidated. It
has become clear that the mere presence of blood stasis is
not a suﬃcient explanation for thrombus formation. Various
alterations related to AF and associated comorbidities as ab-
normal changes in ﬂow, vessel wall, and blood components,
probably drive a hypercoagulable state [42].
Considering the pathophysiology and taking into ac-
count the suspected genetic background in the disease it
could be assumed that mutations or variants in genes of ion
channels, which are of importance in atrial electrophysiolo-
gy, are implicated in AF. This has been conﬁrmed by linkage,
candidate, and genome-wide genetic association studies.
3. Monogenetic Forms of AF
3.1. Familial AF. Studies aimed to identify the pathogenesis
of AF have focused on the familial forms of the disease. In
these rare familial forms diﬀerent loci, as well as mutations
inarangeofgeneshavebeenlinkedtoAF.Variousmutations
in genes encoding sodium channels (SCN5A, SCN1B, and
SCN2B), potassium channels (KCNQ1, KCNE2, KCNJ2,
KCNE5, and KCNA5), natriuretic peptide (ANP) and Con-
nexin 40 have been identiﬁed. Additionally, the culprit genes
at loci on chromosome 10q22 [33], 6q14-16 [34], and 5p15
[35] have yet to be found.
3.1.1. Sodium Channel Mutations. The human cardiac
sodium channel (SCN5A) is responsible for fast depolariza-
tion of cardiomyocytes and has been a therapeutic target
for antiarrhythmic drugs. Initially mutations in SCN5A were
identiﬁed in families with long QT syndrome [8]. Over
the years, more than 200 mutations have been reported in
SCN5A which are associated with variable cardiac diseases
like Brugada syndrome, progressive conduction defect, sick
sinus node syndrome, dilated cardiomyopathy and AF [9].
Genotype-phenotype correlations revealed that most muta-
tionsarelinkedtospeciﬁcclinicalspectrums,butthatclinical
overlapsexistforthesamegeneticdefects[10].BothBrugada
syndrome and long QT syndrome can be complicated with
supraventricular arrhythmias which often include AF [11].
More evidence for the role of mutations in SCN5A in the
pathophysiology of AF was provided by the identiﬁcation
of a family with a dilated cardiomyopathy and AF carrying
a mutation in SCN5A [12]. Additionally, novel mutations
in the same gene were reported in familial forms of AF
with and without structural cardiac disease [13–16]. It was
determined that rare variants in SCN5A are present in nearly
6% of AF probands [14]. In two studies, functional analysis
of the mutation showed a depolarizing shift in steady-state
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function) [15, 16]. A loss of function was suggested by the
study of another variant which revealed a hyperpolarizing
shift in steady-state inactivation resulting in prolongation
of the atrial action potential duration [13]. This delayed
atrial repolarization could induce atrial torsades resulting in
AF. Diﬀerent mechanisms, both loss of function as well as
gain of function, have been suggested in various syndromes.
Furthermore, there is a wide spectrum of mutations which
are associated with overlapping syndromes, suggesting envi-
ronmental or other genetic factors to be of importance in
determining the phenotype.
Interestingly, nonsynonymous variants were identiﬁed in
other sodium channel subunits, two in SCN1B and two in
SCN2B, in patients with AF which were absent in controls
[18].
3.1.2. Mutations in Potassium Channel Genes. The voltage-
gated potassium current has a prominent role in the repolar-
ization of the atrial action potential. Other potassium chan-
nels are of importance for the inward rectiﬁer currents and
thecontroloftherestingpotential.Multiplegain-of-function
aswellasloss-of-functionmutationswithinpotassiumchan-
nelgeneshavebeenidentiﬁed. AmutationinKCNQ1,agene
encoding the pore-forming α subunit of a cardiac voltage-
gated potassium channel, was originally documented as the
causative gene for long QT syndrome [19]. Amutation in the
samegenewastheﬁrstidentiﬁedgeneticdefectlinkedtolone
AF [20]. It was hypothesized that the pathogenic mechanism
consisted of a gain of function by increasing the repolarizing
currentandshorteningoftheatrialactionpotentialduration
[20]. Various other gain of function mutations have subse-
quently been identiﬁed in isolated families in KCNQ1 [21,
22] as well as in other potassium channel genes, including
KCNE2 [23], KCNJ2 [24], and KCNE5 [25]. Additionally, in
another potassium channel gene, KCNA5, loss-of-function
mutations were identiﬁed in a small number of families [26–
28]. Functional analysis of this mutation revealed delayed
action potential repolarization and prolongation of the atrial
action potential duration (a mechanism similar as reported
for a SCN5A mutation [13]).
3.1.3. Atrial Natriuretic Peptide (ANP). In a linkage study of
a family with autosomal dominant AF, a mutation in the
natriuretic peptide precursor gene (NPPA) was identiﬁed
[29]. The mutation produced the loss of a stop codon result-
ing in the expression of a longer peptide. The concentration
of the mutant peptide was 5 to 10 times increased in the
plasma compared to the wild type suggesting a longer half-
lifepotentiallyduetoresistancetodegradation.Inanisolated
whole-heart model, the mutant peptide caused shortening
of the atrial action potential duration (analogous to what is
reported for most of the potassium channel mutations).
Another possible pathophysiological mechanism of the
mutation might involve structural changes resulting in atrial
ﬁbrosis due to exposure to high concentrations of (mutant)
ANP [29].
3.1.4. Connexin 40. The initially discovered genes found in
familial AF were a rare cause of lone AF [43, 44]. Therefore,
additional research focused at other pathogenic pathways.
Attractive genes included the connexins, which are proteins
that form gap junctions and provide low-resistance electrical
coupling between cells. Especially the gene GJA5, coding for
connexin 40, gained interest since it is expressed at high
levels in atria. Furthermore, conduction disturbances have
been identiﬁed in GJA5-knockout mice resulting in atrial
vulnerability and possibly arrhythmogenesis [45]. Sequen-
cing of genomic DNA from cardiac tissue of 15 patients with
idiopathic AF indeed identiﬁed four missense mutations,
of which three were thought to be of somatic origin. The
mutatedproteinwasheterogeneouslydistributedinatrialtis-
sueandaloss-of-functionwashypothesized[30],resultingin
exaggerated dispersion of conduction velocity predisposing
to and sustaining AF. Moreover, a similar genetic mosaicism
in atrial tissue linked to AF was recently reported in one
patient with lone AF for the GJA1 gene, coding for the
connexin 43 protein [46].
3.2. AF in Other Inherited Disorders. In several genetic cardi-
ac syndromes, both with and without structural abnormali-
ties, AF has been described as part of the clinical spectrum.
Short and long QT and Brugada are associated with suprav-
entricular arrhythmias, which often comprise AF. Various
other inherited cardiac disorders are characterized by the
occurrence of AF as hypertrophic cardiomyopathy, ventric-
ular preexcitation and abnormal left ventricle hypertrophy
linked to mutations in the PRKAG gene [11].
4. Complex Genetics of AF
Whereas genetic studies in familial forms of AF have impli-
cated various genes in a limited number of cases, epidemi-
ologic studies in the general population have documented
a genetic component to AF in sporadic AF. Parental AF
was shown to increase the risk for future AF, an association
which was stronger at younger age and for lone AF [47–49].
Candidate gene studies in sporadic AF investigating com-
mon variants in the genome suggested a role for poly-
morphisms in regions implicated in familial AF [17, 31,
32, 50–54]a sw e l la so t h e r s[ 55–63]. An association for
a common polymorphism in SCN5A with paroxysmal AF
was reported, although replication of this ﬁnding is lacking
[17]. Common variants in GJA5 have also been shown to
associate with atrial ﬁbrillation in sporadic AF [31, 32]. The
sample sizes in most of these studies were relatively small
and large replication studies were lacking. Meta-analyses
of studies determining the role of polymorphisms in the
renin-angiotensin system-related gene with AF suggested a
possible association between angiotensin converting enzyme
(ACE) insertion/deletion and AF risk [64, 65]. However a
large replication study recently failed to replicate any of the
reportedassociatedpolymorphisms atthislocusoranyother
locus [66].
Since most of the candidate gene studies have not been
successful, results of genome-wide studies were anxiously
awaited as for many complex diseases [67]. Two sequence
variants on chromosome 4q25 were identiﬁed in the ﬁrst
reported genome-wide association study in AF [36]. These4 Stroke Research and Treatment
variants have been replicated extensively. Two additional
variants in this region were found, and the possibility of
multiple susceptibility signals at this locus was hypothesized
[37]. The reported variants were adjacent to the PITX2
gene, a transcriptional factor critical for determining left-
right asymmetry and for the diﬀerentiation of the left atrium
[68]. Increasing the initial sample size revealed an additional
sequence variant in the ZFHX3 gene in chromosome 16q22
as a risk factor for AF [38]. A third locus was identiﬁed
on chromosome 1q21 in KCNN3, a gene which encodes a
potassium channel protein involved in atrial repolarization
[39]. The variant rs2200733 on 4q25 remained the variant
withthelargesteﬀectsize,withanestimatedoddsratiointhe
range of 1.80 (95% CI 1.50–2.15) [37]/1.90 (95% CI 1.60–
2.26) [69]. Increasing sample sizes in genetic association
studies will potentially reveal yet unknown loci implicated
in AF.
5. Implications for Ischemic Stroke
Ischemic stroke can be categorized into several etiological
subgroups: cardioembolic stroke, large-artery atherosclero-
sis, small-vessel disease, undetermined (cryptogenic, multi-
ple causes, or incomplete evaluation), or other causes [70].
Approximately 20% of ischemic strokes are due to cardiac
embolism mainly caused by atrial ﬁbrillation (AF), which
can be either paroxysmal or persistent with both variants
resulting in a similar stroke risk [71]. It is thought that
some strokes of undetermined origin are actually due to
undiagnosed paroxysmal AF [72] .S i n c es t r o k ec a nb ea
clinical complication of sporadic AF, the risk of stroke is
also increased in familial cases of AF. Other inherited cardiac
disor dersc haract eriz edb yAFcanalsopr esentwithstr ok e.I n
hypertrophic cardiomyopathies, for instance, the stroke risk
is increased and this is directly linked to the occurrence of AF
[73].
Stroke is considered a complex disease where a genetic
componentintheetiologyissuspected.Candidategenestud-
ies in stroke have resulted in largely disappointing ﬁndings
[74]. Findings of a large genome wide association study
in stroke could not be replicated [75, 76]. An association
was reported in a genome-wide association study in stroke
for the initially reported risk variant rs2200733 on 4q25
with AF, OR 1.26 (95% CI 1.17–1.35) [77]. This association
was most pronounced in the cardioembolic subgroup of
stroke. We replicated these ﬁndings and identiﬁed this
variant exclusively in cardioembolic stroke, suggesting that
this variant is indirectly linked to stroke through AF [78].
The eﬀect size of this genetic variant in cardioembolic stroke
issomewhatsmallerthanwhathasbeenreportedforAF,OR:
1.52 (95% CI 1.35–1.71) [77] and 1.47 (95% CI 1.28–1.71)
[78].Thiscouldbeduethefactthatinmostselectedcontrols,
stroke-free status was ensured while AF-free status was not
determined.Additionally,notallpatientswithcardioembolic
stroke are diagnosed with AF (in our replication study this
percentage was 61%). Similar ﬁndings were obtained for
the variant on 16q22 which also confers risk for primarily
cardioembolic stroke [38].
5.1. Inﬂuence of Cryptogenic Stroke?
The initial report on the association of the 4q25 locus with
stroke stated that in subgroup analysis, the association of
the 4q25 locus with stroke remained after all patients who
suﬀered from cardioembolic stroke were excluded [77]. This
studyincludedﬁvestudypopulationstotaling29474controls
and 6222 patients. Our replication study was performed in
six diﬀerent populations with 3750 controls and 4199 pa-
tients.Allstudiesincludedhospital-basedpopulations (apart
from the controls in one cohort in the discovery study). Phe-
notyping was performed according to similar protocols. Po-
tentially the lack of replication after excluding stroke of car-
dioembolic embolism could be due to the somewhat smaller
sample size. Additionally the ﬁndings of the initial report
after excluding cardioembolic stroke might be caused by
phenotypic misclassiﬁcation or ascertainment bias: patients
classiﬁed as having a stroke of undetermined etiology could
in reality have a stroke of (unidentiﬁed) cardioembolic eti-
ologybecauseAFwasnotdetectedduringthehospitalstayor
because the investigation into cardioembolic sources was not
extensively performed. In our replication study, the variants
on 4q25 lacked association with true cryptogenic stroke,
arguing against a large percentage of these patients suffering
from unrevealed cardioembolic stroke. This analysis was not
performed in the initial report. Additionally in our replica-
tion study, we identiﬁed an interaction between cardioem-
bolic stroke and the risk variant on 4q25 supporting the
hypothesis that the relation is mainly caused by this subtype
of stroke.
Since the genotyping of these variants has become com-
mercially available, it might be tempting to oﬀer patients
with stroke of cryptogenic etiology genetic testing for AF in-
ducing variants. Patients carrying the risk variant (of which
the allele frequency is estimated to be 10% in the general
population) could, for example, be more extensively studied
for paroxysmal AF. Our results do not provide evidence for
performing such individually based genotyping since no as-
sociation was identiﬁed in cryptogenic stroke patients.
5.2. Stroke as a Phenotype or Stroke as a Conglomerate of Phe-
notypes. The ﬁndings from these genetic association studies
underlinethatgeneticriskfactorsmaypredisposetoapartic-
ular subgroup of stroke. The fact that a variant on chromo-
some 9 associated with myocardial infarction and coronary
arterydiseasealsoisassociatedwithstrokeduetolarge-vessel
atherosclerotic disease emphasizes this assumption [79, 80].
Stroke is a heterogeneous disorder, and this heterogeneity
might be the reason for the disappointing results in genetic
associationstudiesinthestrokeﬁeldsofar.Itcanbeassumed
that genetic risk factors are implicated only in subgroups
of stroke, and, therefore, analyzing each subgroup is of im-
portance. In order to obtain convincing results from GWAS,
accurate stroke phenotyping and large sample sizes for each
s t r o k es u b t y p ew i l lb er e q u i r e d .
5.3. Stroke as a Vascular Endpoint. Stroke can be regarded as
the clinical outcome of other underlying diseases; this seemsStroke Research and Treatment 5
applicable not only to AF and cardioembolic stroke but also
for stroke due to large-vessel disease and atherosclerosis.
One could argue that data of various disease traits that share
underlying pathogenic mechanisms could be combined
in meta-analyses of genome-wide association studies to
increase power. Moreover, it could be considered to analyze
cases of underlying diseases together with cases of the as-
sociated clinical outcome. For instance, data obtained in
genome-wide association studies in AF can be merged with
the data of all cardioembolic stroke cases. Similarly, coronary
artery disease, peripheral artery disease and stroke due to
large-vessel disease could be jointly examined. This does
not entirely exclude the possibility that genetic variants will
be identiﬁed for ischemic stroke in general. However, the
other approaches (combining vascular diseases or merging
risk factors and their outcomes) could increase power and
could eventually lead to the identiﬁcation of genetic pol-
ymorphisms conferring risk for (subtypes of) stroke. Al-
though typically this will lead to ﬁndings of small eﬀect size,
this does not imply that the biological relevance cannot be
greater than the genetic eﬀect.
In complex diseases (asstroke), it is assumed that various
environmental factors together with genetic variants can
result in a certain disease phenotype. Interfering with several
(but not necessarily all) of these factors might already result
in reducing risk and, therefore, less clinical outcomes in
the general population. Identifying the pathophysiological
meaning of a genetic variant associated with AF could po-
tentially lead to new therapeutic targets in AF and indirectly
lead to a reduction in cardioembolic stroke.
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